Aim:To assess the role of several genetic factors in combination with an environmental factor as modulators of prostate cancer risk.We focus on allele variants of low-penetrance genes associated with cell control,the ...Aim:To assess the role of several genetic factors in combination with an environmental factor as modulators of prostate cancer risk.We focus on allele variants of low-penetrance genes associated with cell control,the detoxifica- tion processes and smoking.Methods:In a case-control study we compared people carrying p53cd72 Pro allele, CYP1A1 M1 allele and GSTM1 null genotypes with their prostate cancer risk.Results:The joint risk for smokers carrying Pro* and Ml*,Pro* and GSTMlnull or GSTM1 null and CYP1A1 Ml* variants was significantly higher (odds ratio [OR]:13.13.95% confidence interval [CI]:2.41-71.36;OR:3.97,95% CI:1.13-13.95 and OR:6.87. 95% CI:1.68-27.97,respectively)compared with that for the reference group,and for non-smokers was not significant. OR for combinations among p53cd72,GSTM1 and CYP1A1 M1 in smokers were positively and significantly associated with prostate cancer risk compared with non-smokers and compared with the putative lowest risk group(OR:8.87,95% CI:1.25-62.71).Conclusion:Our results suggest that a combination of p53cd72,CYP1A1,GSTM1 alleles and smoking plays a significant role in modified prostate cancer risk on the study population,which means that smokers carrying susceptible genotypes might have a significantly higher risk than those carrying non-susceptible genotypes.展开更多
文摘Aim:To assess the role of several genetic factors in combination with an environmental factor as modulators of prostate cancer risk.We focus on allele variants of low-penetrance genes associated with cell control,the detoxifica- tion processes and smoking.Methods:In a case-control study we compared people carrying p53cd72 Pro allele, CYP1A1 M1 allele and GSTM1 null genotypes with their prostate cancer risk.Results:The joint risk for smokers carrying Pro* and Ml*,Pro* and GSTMlnull or GSTM1 null and CYP1A1 Ml* variants was significantly higher (odds ratio [OR]:13.13.95% confidence interval [CI]:2.41-71.36;OR:3.97,95% CI:1.13-13.95 and OR:6.87. 95% CI:1.68-27.97,respectively)compared with that for the reference group,and for non-smokers was not significant. OR for combinations among p53cd72,GSTM1 and CYP1A1 M1 in smokers were positively and significantly associated with prostate cancer risk compared with non-smokers and compared with the putative lowest risk group(OR:8.87,95% CI:1.25-62.71).Conclusion:Our results suggest that a combination of p53cd72,CYP1A1,GSTM1 alleles and smoking plays a significant role in modified prostate cancer risk on the study population,which means that smokers carrying susceptible genotypes might have a significantly higher risk than those carrying non-susceptible genotypes.
